TUDRIQEV (vusolimogene oderparepvec-wtpg) granted accelerated approval, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1 blocking antibody-based regimen (Aug 6 2026).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (2/6/26) through T+0. Run-up high $11.63 on 6/26/26, low $1.7 on 4/13/26 (T-120 to T-1). FDA decision 8/6/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-08-06
OutcomeApproved
Drug / candidateTUDRIQEV (vusolimogene oderparepvec-wtpg)
IndicationUnresectable advanced cutaneous melanoma after progression on a PD-1 blocking antibody
CompanyReplimune Group, Inc.
Market-cap tierSmall
120-day run-up (T-120→T-1)-30.2%
Cohort decision-day move (history)3.6% median (n=279)
This was the third review cycle. The FDA issued a Complete Response Letter on July 21, 2025, a second action letter on April 10, 2026, and accepted the Class 1 resubmission on June 26, 2026 with a goal date of August 2, 2026. The agency acted on August 6, four days past the goal date. Approval is accelerated, based on objective response rate and duration of response in the single-arm IGNYTE study (ORR 24%, median duration of response 14.1 months), and continued approval may be contingent on verifying benefit in the confirmatory Phase 3 IGNYTE-3 trial, whose primary endpoint is overall survival and which is due to complete in 2030. An advisory committee voted 10 to 3 on July 30, 2026 that the IGNYTE results were evaluable and clinically meaningful. The label carries no boxed warning and no REMS.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.